Ependymoma
Glioma derived from EPENDYMOGLIAL CELLS that tend to present as malignant intracranial tumors in children and as benign intraspinal neoplasms in adults. It may arise from any level of the ventricular system or central canal of the spinal cord. Intracranial ependymomas most frequently originate in the FOURTH VENTRICLE and histologically are densely cellular tumors which may contain ependymal tubules and perivascular pseudorosettes. Spinal ependymomas are usually benign papillary or myxopapillary tumors. (From DeVita et al., Principles and Practice of Oncology, 5th ed, p2018; Escourolle et al., Manual of Basic Neuropathology, 2nd ed, pp28-9)
Subtype terms (1)
More specific conditions that are subtypes of Ependymoma in the MeSH hierarchy.
Drugs by status
Approved for this indication (1)
Phase 3 trials (10)
Phase 2 trials (54)
- s-methionine
- thalidomide
- ly-3023414
- axitinib
- antineoplaston AS2-1
- atengenal
- olaparib
- brigatinib
- bvd-523
- irinotecan
- erdafitinib
- lapatinib
- ritonavir
- Imetelstat
- indoximod
- nivolumab
- potassium iodide
- larotrectinib
- marizomib
- memantine
- nktr-214
- palbociclib
- pemetrexed
- pep-cmv
- acetaminophen
- zarnestra
- sunitinib
- lopinavir
- vemurafenib
- celecoxib
- +24 more
Phase 1 trials (57)
- azacitidine
- aglatimagene besadenovec
- apx005m
- urea
- lenalidomide
- cilengitide
- ef5
- gemcitabine
- fluorouracil
- tacrolimus
- trametinib
- aldesleukin
- imiquimod
- Filgrastim
- autologous natural killer cells
- ispinesib
- pembrolizumab
- ribociclib
- gadopenteate dimeglumine
- alisertib
- o6-benzylguanine
- ibrutinib
- trastuzumab
- rhenium liposome
- ro4929097
- sgt-53
- sirolimus
- mycophenolate
- sonidegib
- stem cells
- +27 more
Organizations
Organization Involved with Phase 3 Indications (5)
Organization Involved with Phase 2 Indications (42)
- Takeda
- OSI Pharmaceuticals
- Astellas
- AstraZeneca
- Eli Lilly
- Axelar AB
- The Christie NHS Foundation Trust
- National Institutes of Health (NIH)
- Augusta University
- Brown University
- Burzynski Research Institute
- Case Western Reserve University
- Children's Cancer and Leukaemia Group
- Harvard University
- Eastern Cooperative Oncology Group
- Emory University
- Florida International University
- Herbert Irving Comprehensive Cancer Center
- Johns Hopkins University
- Northwestern University
- Pediatric Brain Tumor Consortium
- Southwest Oncology Group
- University of Florida
- University of Leeds
- University of Milan
- University of Rochester
- University of Southern California
- University of Birmingham
- Wayne State University
- Mayo Clinic
- +12 more
Organization Involved with Phase 1 Indications (24)
- Millennium Pharmaceuticals
- Candel Therapeutics
- Novartis
- Oncoceutics, Inc.
- Apexigen, Inc.
- University of Pennsylvania
- Cancer and Leukemia Group B (CALGB)
- Cornell University
- Duke University
- University of Washington
- Thomas Jefferson University
- University of Toronto
- University of Colorado, Denver
- University of Minnesota
- NewLink Genetics Inc
- City of Hope National Medical Center
- University of Colorado
- The Andrew McDonough B+ Foundation
- Musella Foundation
- Memorial Sloan-Kettering Cancer Center
- Solving Kids’ Cancer
- A Kids Brain Tumor Cure
- American Lebanese Syrian Associated Charities
- Ty Louis Campbell Foundation
Organization Involved with Other Experimental Indications (6)